Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Oct 13, 2022 10:01am
174 Views
Post# 35022035

RE:RE:RE:Bank of America

RE:RE:RE:Bank of AmericaHe has spoken with management in the past so they know him. I think it was just the operator who did not realize he was not an analyst at BAC. That being said, he is actually a very good analyst. He was surprised he got on so he had not prepared a bunch of questions which he now regrets.

SABBOBCAT wrote: Hahaha that is hilarious. Slightly disappointing but awesome at the same time. You should have just left it and let him keep asking questions in future calls. 

SPCEO1 wrote: I know the BAC "analyst" who asked a question. He is not an analyst but just a  shareholder who works at BAC, and apparently the operator was not aware he was not an analyst and let him on the call.

Biobob wrote: That was the best news about this call. They bothered to ask a question... so they are curious about Th1902... maybe smart people like Soleus are starting to smell something.  I agree with Wino that we should be optimist in light of what we eard.

 




<< Previous
Bullboard Posts
Next >>